PathWhiz

PathWhiz ID	Pathway	Meta Data
PW127504 View Pathway	drug action Tipranavir Action Pathway Homo sapiens Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor used to treat HIV-1 resistant to more than 1 protease inhibitor. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. The HIV virus binds and penetrates the host cell. Viral RNA is transcribed into viral DNA via reverse transcriptase. Viral DNA enters the host nucleus and is integrated into the host DNA via integrase. The DNA is then transcribed, creating viral mRNA. Viral mRNA is translater into the gag-pol polyprotein. HIV protease is synthesized as part of the Gag-pol polyprotein, where Gag encodes for the capsid and matrix protein to form the outer protein shell, and Pol encodes for the reverse transcriptase and integrase protein to synthesize and incorporate its genome into host cells. HIV-1 protease cleaves the Gag-pol polyprotein into 66 molecular species, including HIV-1 protease, integrase, and reverse transcriptase. Tipranavir competitively binds to the active site of HIV-1 protease. This inhibition prevents the HIV virion from fully maturing and becoming infective. Using the lipid bilayer of the host cell, a virus is formed and released. The inhibition of HIV-1 protease prevents the necessary molecular species from forming, therefore preventing maturation and activation of viral particles. This forms immature, non-infectious viral particles, therefore, Tipranavir prevents the virus from reproducing. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: March 22, 2023 at 11:56 Last Updated: March 22, 2023 at 11:56
PW145032 View Pathway	drug action Tipranavir Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:57 Last Updated: October 07, 2023 at 14:57
PW176147 View Pathway	metabolic Tipranavir Predicted Metabolism Pathway new Homo sapiens Metabolites of Tipranavir are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: November 29, 2023 at 14:19 Last Updated: November 29, 2023 at 14:19
PW145656 View Pathway	drug action Tirbanibulin Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:19 Last Updated: October 07, 2023 at 16:19
PW122410 View Pathway	drug action Tirofiban Action Homo sapiens Tirofiban is a platelet aggregation inhibitor drug sold under the name Aggrastat. It is specifically a small molecule that inhibits the glycoprotein IIb/IIIa receptor of platelets. It is administered intravenously, and can act to decrease platelet aggregation by over 90% after the infusion, and can help prevent aggregation for up to two days after administration. In the vein, tirofiban causes a conformational change in the integrins on the surface of activated platelets. This prevents the binding of fibrinogen to these integrins, which in turn prevents the platelets from being held together by these fibrinogen fibres. The conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Eponine Oler Created On: March 25, 2019 at 21:24 Last Updated: March 25, 2019 at 21:24
PW000293 View Pathway	drug action Tirofiban Action Pathway Homo sapiens Tirofiban is a platelet aggregation inhibitor drug sold under the name Aggrastat. It is specifically a small molecule that inhibits the glycoprotein IIb/IIIa receptor of platelets. It is administered intravenously, and can act to decrease platelet aggregation by over 90% after the infusion, and can help prevent aggregation for up to two days after administration. In the vein, tirofiban causes a conformational change in the integrins on the surface of activated platelets. This prevents the binding of fibrinogen to these integrins, which in turn prevents the platelets from being held together by these fibrinogen fibres. The conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 22, 2013 at 10:45 Last Updated: August 22, 2013 at 10:45
PW128069 View Pathway	drug action Tirofiban Action Pathway (new) Homo sapiens Tirofiban is a platelet aggregation inhibitor, also known under the brand name Aggrastat, it is used to prevent thrombotic events from occurring in those who are high-risk. It is administered intravenously and acts as an antagonist of the platelet glycoprotein IIb/IIIa receptor, this receptor is responsible for platelet aggregation in order to form a thrombus, without this signal from the receptor it stops aggregation. This inhibition created by the drug will cease once the drug is no longer infused into the patient's bloodstream. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Selena Created On: July 13, 2023 at 09:38 Last Updated: July 13, 2023 at 09:38
PW144884 View Pathway	drug action Tirofiban Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:38 Last Updated: October 07, 2023 at 14:38
PW146190 View Pathway	drug action Titanium dioxide Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:37 Last Updated: October 07, 2023 at 17:37
PW128525 View Pathway	drug action Tivozanib Action Pathway Homo sapiens Tivozanib, marketed as FOTIVDA, is a kinase inhibitor primarily used to treat renal cell carcinoma (RCC) in adult patients who have not responded to previous systemic therapies or have experienced relapsed disease. RCC is a relatively common cancer that predominantly affects adults between the ages of 65 to 74. Tivozanib offers hope as a therapeutic option for individuals with advanced RCC who have not had success with other treatments. It is approved in the United States for those who have undergone two or more systemic therapies for RCC. In the UK and some other countries, it is indicated as the first-line therapy for adults with advanced RCC who have not previously received VEGFR and mTOR pathway inhibitors after their disease has progressed following one prior treatment with cytokine therapy. Tivozanib works by inhibiting growth factor receptors, specifically targeting renal cell carcinoma. In preclinical studies using mice and rats, tivozanib demonstrated its ability to inhibit tumor angiogenesis, slow tumor growth, and reduce vascular permeability. However, it's important to note that tivozanib can often lead to hypertension, which must be managed before initiating therapy. Additionally, while a cardiac QT segment prolongation was reported in a tivozanib cardiac safety study, these reactions were not deemed clinically serious. Furthermore, clinical studies have shown a decrease in serum soluble VEGFR2 (sVEGFR2) levels over time with tivozanib exposure, and sVEGFR2 can serve as a pharmacodynamic marker of VEGFR inhibition. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Dorsa Yahya Rayat Created On: September 01, 2023 at 13:19 Last Updated: September 01, 2023 at 13:19